Oxford Biomedica is a leading gene and cell therapy company focused on developing innovative treatments for oncology, ophthalmology, and central nervous system (CNS) disorders. The company operates in the biopharmaceutical market, serving clients ranging from large pharmaceutical companies to smaller biotech firms. Its business model is built on leveraging its proprietary delivery platform to create a portfolio of product candidates, which are then developed through partnerships. These partnerships generate multiple income streams, including upfront milestone payments, development and production fees, and potential royalties on future product sales.

Oxford Biomedica also invests in preclinical research and development to discover new potential products. The company plans to advance its wholly-owned products through spin-outs and out-licensing opportunities. Additionally, it is expanding its bioprocessing capabilities with the construction of the new OxBox facility, which will feature GMP clean room suites, fill and finish suites, and QC laboratories.

The company makes money through a combination of milestone payments, development fees, production fees, and royalties from its partnerships. It aims to continue investing in its platform and exploring new opportunities for growth.

Keywords: gene therapy, cell therapy, oncology, ophthalmology, CNS disorders, biopharmaceutical, delivery platform, partnerships, OxBox facility, spin-outs.